News
OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.
Taipei, Taiwan – 31 January 2013 – A recent paper …
Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
Breast Cancer New Drug:OBI-822/821 received Taiwan FDA Approval for entering …
DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD
DIFICID® (Fidaxomicin) Approved by Taiwan Department of Health for the …